newsfilter
← Latest News
ACCESS Newswire·

Sibannac, Inc. (OTCID:SNNC) Enters Into Non-Binding Letter of Intent for Strategic Collaboration and Potential Reverse Merger Focused on Advancing Patient Health Potential

SNNC
  • Sibannac, Inc. (OTCID:SNNC) entered a non-binding Letter of Intent with two strategic partners to explore a business relationship & transaction centered on patient health via an expanding clinician network.
  • One partner is an established developer of turnkey clinical platforms serving hundreds of clinicians who prescribe GLP-1 medications & groups engaged in peptide research.
  • The second partner operates a network offering at-home genetic testing for GLP-1 response & tolerability, customized nutraceuticals, a health-optimization phone app, & related laboratory services.
  • Discussions focus on forming a new Arizona limited liability company to serve as a special purpose vehicle (SPV) that will reverse-merge into Sibannac or effect a business combination.
  • CEO David Mersky stated the combined platform aims to integrate clinical infrastructure, genetic insights, personalized nutraceuticals, & digital health tools to help patients achieve maximum health potential.
  • The Company believes the completed transaction has the potential to contribute meaningful revenue to Sibannac, though no guarantees are provided regarding future performance.